| Literature DB >> 31456226 |
Adrian Pilatz1,2, Jill Kilb1, Huelya Kaplan3, Daniela Fietz2,4, Hamid Hossain5,6, Christian G Schüttler7, Thorsten Diemer1,2, Martin Bergmann2,4, Eugen Domann5, Wolfgang Weidner1, Florian Wagenlehner1,2, Hans-Christian Schuppe1,2.
Abstract
Considering infection/inflammation to be an important risk factor in male infertility, the aim of this study was to make a comprehensive evaluation of the prevalence of urogenital tract infection/inflammation and its potential impact on sperm retrieval in azoospermic patients. In this prospective study, 71 patients with azoospermia were subjected to an extensive andrological workup including comprehensive microbiological diagnostics (2-glass test, semen, testicular swab and testicular tissue analysis) and testicular biopsy/testicular sperm extraction (TESE). Medical history suggested urogenital tract infection/inflammation in 7% of patients, 11% harboured STIs, 14% showed significant bacteriospermia, 15% had seminal inflammation, 17% fulfilled the MAGI definition, and 27% had relevant pathogens. At the testicular level, 1 patient had a swab positive for bacteria, no viruses were detected, tissue specimens never indicated pathogens, whereas histopathology revealed focal immune cell infiltrates in 23% of samples. Testicular sperm retrieval rate was 100% in obstructive and 46% in nonobstructive azoospermia. None of the infection/inflammation-related variables was associated with the success of sperm retrieval or inflammatory lesions in the testis. The high prevalence of urogenital infection/inflammation among azoospermic men underpins their role as significant aetiologic factors in male infertility. However, this observation does not refer to the chances of sperm retrieval at the time of surgery/TESE.Entities:
Keywords: TESE; azoospermia; genital tract inflammation; infertility; male accessory gland infection
Mesh:
Year: 2019 PMID: 31456226 PMCID: PMC7147116 DOI: 10.1111/and.13401
Source DB: PubMed Journal: Andrologia ISSN: 0303-4569 Impact factor: 2.775
Figure 1Illustration of diagnostic procedures regarding assessment of infection/inflammation in the urogenital tract
Demographics of the study population
| Parameter | Median (IQR), or |
|---|---|
| Patient's age (years) | 34 (30–38) |
| Body size (cm) | 180 (175–184) |
| BMI (kg/m2) | 26.0 (23.6–29.4) |
| Body weight (kg) | 82 (75–95) |
| Age of female partner (years) | 30 (27–34) |
| Sexually active | 71 (100%) |
| Current female partner | 71 (100%) |
| Duration of current partnership (years) | 7 (4–10) |
| Married | 54 (76%) |
| Duration of marriage (years) | 2 (0–3) |
| Duration of unwanted childlessness (years) | 2 (1.5–3) |
| Number of brothers | 1 (0–2) |
| Number of sisters | 1 (0–1) |
| Lifetime sexual partners | 5 (3–10) |
| History of miscarriage in family | 11 (16%) |
| Involuntary childlessness in family | 11 (16%) |
| Alcohol consumption | Frequently (Rarely–Occasionally) |
| Previous smokers | 17 (24%) |
| Current smokers | 18 (25%) |
| History of drug abuse (cannabis) | 9 (13%) |
| Current drug abuse (cannabis) | 1 (1%) |
| Exposure to pollutants | 15 (21%) |
| Heat | 4 (6%) |
| Radioactivity | 1 (1%) |
| Solvents | 6 (9%) |
| Multiple | 3 (4%) |
Data from n = 68 patients.
Overview of clinical risk factors for azoospermia
| Factor | Patients (%) |
|---|---|
| History of cryptorchidism | 16 (22) |
| Genetic disorders (Klinefelter syndrome, Y chromosome microdeletion [AZFc]) | 12 (17) |
| History of cancer | 8 (11) |
| History of urogenital tract infection/inflammation | 5 (7) |
| Unexplained | 35 (49) |
Five patients with multiple risk factors.
Andrological parameters of the study population
| Parameter | Median (IQR), or |
|---|---|
| Semen | |
| Volume (ml) | 2.5 (1.8–3.6) |
| pH value | 7.6 (7.3–7.8) |
| Sperm concentration (million/ml) | 0 (0–0.0) |
| Peroxidase‐positive leucocytes (million/ml) | 0.1 (0–0.1) |
| Fructose (µmol/ejaculate) | 36.8 (19.7–64.2) |
| Glucosidase (mU/ejaculate) | 29.5 (17.7–52.8) |
| Elastase (ng/ml) | 49 (18–153) |
| Zinc (µmol/ejaculate) | 9.5 (6.1–17.4) |
| Hormones | |
| FSH (mU/ml) | 19.8 (13.8–29.1) |
| LH (mU/ml) | 7.3 (4.3–12.7) |
| Testosterone (nmol/L) | 12.2 (8.8–15.5) |
| Free testosterone (pmol/L) | 241.2 (197.1–296.3) |
| SHBG (nmol/L) | 29.2 (24.4–41.6) |
| Albumin (g/L) | 47.6 (45.9–49.1) |
| Oestradiol (pmol/L) | 110.1 (88.1–135.8) |
| Prolactin (uIU/ml) | 163 (123–201) |
| Ultrasound | |
| Total testicular volume (ml) | 14.2 (7.9–19.9) |
| Mean testicular volume (ml) | 7.2 (4.1–10.2) |
| Epididymal head height (mm) | 9.8 (7.9–11.6) |
| Epididymal head thickness (mm) | 7.9 (6.8–9.7) |
| PSV testicular artery (cm/s) | 6.8 (5.2–8.3) |
| PSV intratesticular arteries (cm/s) | 4.3 (3.5–5.1) |
| Right varicocele | 0 (0%) |
| Left varicocele | 19 (27%) |
| Subclinical | 12 (17%) |
| Grade I | 2 (3%) |
| Grade II | 2 (3%) |
| Grade III | 3 (4%) |
Abbreviation: PSV, peak systolic velocity.
n = 70.
n = 69.
Six patients with single testis excluded.
Seven patients with single epididymis excluded.
Synopsis of clinically relevant pathogens in the urogenital tract
| Patient | VB1 | VB3 | Ejaculate | Testicular swabs | Testicular tissue |
|---|---|---|---|---|---|
| 2 |
| Ø | Ø | Ø | Ø |
| 6 | Ø | Ø |
| Ø | Ø |
| 7 |
| Ø | Ø | Ø | Ø |
| 10 |
|
|
| Ø | Ø |
| 11 |
|
|
| Ø | Ø |
| 23 |
|
|
| Ø | Ø |
| 24 |
|
|
| Ø | Ø |
| 28 | Ø | Ø | Ø |
| Ø |
| 30 | Ø | Ø |
| Ø | Ø |
| 35 |
| Ø | Ø | Ø | Ø |
| 37 | Ø | Ø |
| Ø | Ø |
| 44 |
|
|
| Ø | Ø |
| 48 | Ø | Ø |
| Ø | Ø |
| 63 |
|
| Ø | Ø | Ø |
| 64 | Ø |
| Ø | Ø | Ø |
| 69 | Ø | Ø |
| Ø | Ø |
| 77 | Ø | Ø |
| Ø | Ø |
| 82 |
|
|
| Ø | Ø |
| 103 | Ø | Ø |
| Ø | Ø |
Association of parameters indicating infection/inflammation and testicular sperm retrieval
| Parameter | OA ( | NOA positive ( | NOA negative ( |
|
|---|---|---|---|---|
| Lifetime sexual partners, median (ICR) | 6 (3–15) | 5 (3–10) | 5 (2–10) | .915 |
| History of urogenital tract infection/inflammation | 2/15 (13%) | 1/26 (4%) | 2/30 (7%) | .517 |
| Amount of leucocytes in VB1 (cells/hpf) | 1.0 (0.5–3.5) | 0.5 (0.0–1.0) | 0.5 (0.0–1.0) | .127 |
| Amount of leucocytes in VB3 (cells/hpf) | 0.5 (0.5–1.0) | 0.5 (0.0–2.0) | 0.5 (0.0–0.5) | .368 |
| Leucocyturia > 20 cells/hpf | 1/15 (7%) | 0/23 (0%) | 0/27 (0%) | .184 |
| Peroxidase‐positive leucocytes, median (ICR) in 106/ml | 0.0 (0.0–0.4) | 0.1 (0.0–0.1) | 0.0 (0.0–0.2) | .957 |
| Leucocytospermia (≥106/ml) | 2/15 (13%) | 1/26 (4%) | 1/30 (3%) | .345 |
| Elastase, median (ICR) in ng/ml | 71 (22–264) | 47 (28–77) | 40 (14–190) | .460 |
| Elastase > 250 ng/ml | 4/14 (29%) | 1/26 (4%) | 6/30 (20%) | .085 |
| Relevant inflammation in urine/semen (leucocytospermia, VB3 > 20 cells/hpf, elastase > 250 ng/ml) | 4/15 (27%) | 1/26 (4%) | 6/30 (20%) | .101 |
| Presence of bacteriospermia (≥103 CFU/ml) | 9/15 (60%) | 12/26 (46%) | 9/30 (30%) | .139 |
| Amount of pathogens in bacteriospermia (CFU/ml) | 2,200 (0–15,400) | 0 (0–3,300) | 0 (0–2,750) | .169 |
| Presence of relevant bacteriospermia | 4/15 (27%) | 1/26 (4%) | 5/30 (17%) | .112 |
| Presence of STIs in urogenital tract | 1/15 (7%) | 4/26 (15%) | 3/30 (10%) | .668 |
| Presence of pathogens >105 CFU/ml in urine specimens | 1/15 (7%) | 1/26 (4%) | 1/30 (3%) | .865 |
| Presence of pathogens in swabs/testicular tissue | 1/15 (7%) | 0/26 (0%) | 0/30 (0%) | .151 |
| All pathogens in urogenital tract | 9/15 (60%) | 14/26 (54%) | 10/30 (33%) | .153 |
| Clinically relevant pathogens in urogenital tract | 5/15 (33%) | 6/26 (23%) | 8/30 (27%) | .775 |
| Fulfilled MAGI definition | 6/15 (40%) | 1/26 (4%) | 5/30 (17%) |
|
| NIH‐CPSI score total score | 3 (2–7) | 1 (0–2) | 3 (0–8) |
|
| Focal inflammatory lesions in testicular biopsy specimens (sparse, dense) | 4/15 (27%) | 8/26 (31%) | 4/30 (13%) | .271 |
Bold values specify significant parameters.
Abbreviation: hpf, high‐power field.
n = 68.
n = 62.
n = 65.
n = 70.
Urethral commensals (Table S1) excluded.
n = 55.